ReviewFrontiers in microbiology2025
Gut microbiota and viral respiratory infections: microbial alterations, immune modulation, and impact on disease severity: a narrative review.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Gut Microbiota and Probiotics in Influenza: A Narrative Review of Mechanisms and Emerging Evidence.Viruses · 2026Review
- The Diabetes-Viral Respiratory Syndemic: Pathophysiological Insights and Precision Management: A Scoping Review.Medicina (Kaunas, Lithuania) · 2026Article
- Review
- Interplay between viral infections and gut microbiota dysbiosis: Mechanisms and therapeutic potential.World journal of gastroenterology · 2026Review
- Gut microbiota and serum metabolome in children with human metapneumovirus infection.Frontiers in immunology · 2026Article
- Review
- A New Perspective on Nasal Microbiota Dysbiosis-Mediated Allergic Rhinitis: From the Mechanism of Immune Microenvironment Remodeling to Microbiota-Targeted Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Comparative meta-transcriptomic analysis of nasal and anal microbiota in respiratory syncytial virus mono and co-infected children.BMC microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory viral infections are a major public health concern, accounting for millions of infections annually and contributing significantly to global morbidity and mortality. Influenza and respiratory syncytial virus (RSV) have long been recognized as critical pathogens, while the recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the COVID-19 pandemic. These viruses typically affect both the upper and lower respiratory tracts and can cause a broad spectrum of clinical manifestations, ranging from mild symptoms to severe respiratory failure and multi-organ dysfunction. Gastrointestinal symptoms are also frequently reported, suggesting a potential link between respiratory viruses and gut microbiota alterations. This connection highlights the role of the gut microbiota in disease pathophysiology. This narrative review summarizes current evidence on gut microbiota changes associated with SARS-CoV-2, influenza, and RSV infections. It further explores the microbiota's role in immune regulation and host homeostasis, and discusses the potential of microbiota-targeted strategies in the prevention and management of acute respiratory syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.